PRESS RELEASE published on 02/20/2025 at 18:30, 11 months 11 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Theraclion secures financing of €6 million through a convertible bond loan with firm commitments from historical shareholders, Furui and Unigestion. CEO Martin Deterre highlights strategic priorities for revenue growth and FDA approval Financing Strategic Priorities FDA Approval Theraclion Convertible Bond Loan
PRESS RELEASE published on 02/20/2025 at 18:30, 11 months 11 days ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) Theraclion sécurise un financement de 6 millions d'euros auprès de ses actionnaires historiques grâce à un emprunt obligataire convertible. Objectif : poursuite R&D et développement commercial Actionnaires Financement Emprunt Theraclion Obligataire Convertible
BRIEF published on 02/07/2025 at 18:35, 11 months 24 days ago Publication des comptes ajustés de Theraclion pour le premier semestre 2024 Trésorerie Theraclion Comptes Ajustés Ultrasons Focalisés Marche Des Varices
BRIEF published on 02/07/2025 at 18:35, 11 months 24 days ago Publication of Theraclion's adjusted accounts for the first half of 2024 Treasury Theraclion Adjusted Accounts Focused Ultrasound Varicose Veins Walk
PRESS RELEASE published on 02/07/2025 at 18:30, 11 months 24 days ago Informations privilégiées / Communiqué sur comptes, résultats Publication des comptes ajustés du premier semestre 2024 de Theraclion, société innovante en thérapie ultrasonique pour varices. Focus sur recentrage stratégique et résultats financiers Stratégie Résultats Financiers Theraclion Varices Comptes Ajustés
BRIEF published on 01/06/2025 at 19:06, 1 year ago Theraclion 2024 Review: Progress and Challenges Turnover Theraclion SONOVEIN® FDA Clinical Trial Product Maturity
BRIEF published on 01/06/2025 at 19:06, 1 year ago Bilan 2024 de Theraclion : avancées et défis Chiffre D'affaires Theraclion SONOVEIN® Essai Clinique FDA Maturité Produit
PRESS RELEASE published on 01/06/2025 at 19:01, 1 year ago Informations privilégiées / Communiqué sur comptes, résultats THERACLION fait le bilan de ses réalisations en 2024, mettant en avant les avancées de son essai clinique pivot FDA et la maturité de son produit SONOVEIN® pour traitement des varices 2024 Essai Clinique Theraclion SONOVEIN® Varices
BRIEF published on 10/30/2024 at 19:05, 1 year 3 months ago Theraclion: Results for the First Half of 2024 and Strategic Outlook Financial Results Theraclion SONOVEIN FDA America Marketing 2025
BRIEF published on 10/30/2024 at 19:05, 1 year 3 months ago Theraclion : Résultats du Premier Semestre 2024 et Perspectives Stratégiques Résultats Financiers Theraclion SONOVEIN FDA Amérique Commercialisation 2025
Published on 02/04/2026 at 02:15, 4 hours 40 minutes ago Future Fuels Announces $2 Million LIFE Flow-Through Offering
Published on 02/04/2026 at 00:00, 6 hours 55 minutes ago Sintana Energy Inc. Announces VMM-37 Resolution
Published on 02/03/2026 at 23:30, 7 hours 25 minutes ago FutureGen Industries Retains Market-Making Services
Published on 02/03/2026 at 23:12, 7 hours 43 minutes ago Appointment of Credit Advisor for Stage 1 Operations
Published on 02/03/2026 at 22:30, 8 hours 25 minutes ago Green Bridge Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$4 Million
Published on 02/04/2026 at 02:05, 4 hours 50 minutes ago Saudi Arabia Preparing for AlUla Emerging Market Economies Conference to be Held February 8-9, 2026
Published on 02/04/2026 at 00:42, 6 hours 12 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3X - Initial Director's Interest Notice
Published on 02/03/2026 at 20:57, 9 hours 58 minutes ago EQS-Adhoc: tick Trading Software AG adjusts forecast for the current 2025/2026 fiscal year
Published on 02/03/2026 at 20:36, 10 hours 18 minutes ago Freelance.com: Agenda de communication financière 2026-2027
Published on 02/03/2026 at 18:00, 12 hours 55 minutes ago Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
Published on 02/03/2026 at 17:45, 13 hours 10 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 02/03/2026 at 17:45, 13 hours 10 minutes ago Chiffre d’affaires 2025 en croissance à 11,2 M€ (+5%)
